logo.gif (1910 bytes) submenu.gif (821 bytes)
support.gif (725 bytes)
toolbar.gif (1583 bytes)
toolbar_spacer.gif (89 bytes)
pix.GIF (45 bytes)

pix.GIF (45 bytes)

Immunetics Qualicode™ and C6 ELISA Kit References Available

Cysticercosis

  1. Tsang VCW, Brand JA, and Boyer AE . Enzyme-Linked Immunoelectrotransfer Blot Assay and Glycoprotein Antigens for Diagnosing HumanCysticercosis (Taenia solium). J. Infect. Dis. 159(1): 50-59, 1989.
  2. Diaz JF, et al. Immunodiagnosis of Human Cysticercosis (Taenia solium): A Field Comparison of an Antibody-Enzyme-Linked Immunosorbent Assay(ELISA), and Antigen-ELISA, and an Enzyme-Linked Immunoelectrotransfer Blot (EITB) Assay in Peru. Am. J. Trop. Med. Hyg. 46(5): 610-615, 1992.
  3. Diaz JF., et al. Epidemiology of Taeniasis and Cysticercosis in a Peruvian Village. Am. J. Epidemiol. 135(8): 875-882, 1992.
  4. Garcia HH, et al. Cysticercosis as a Major Cause of Epilepsy in Peru. The Lancet 341: 197-200, 1993.

    5. Not Cited in Package Insert Sheet

  5. Garcia HH. Diagnosis of cysticercosis in endemic regions. The Lancet 338:549-51, 1991.

HIV-1/2
  1. Tsang VCW, Peralta JM, Simons AR. Enzyme-linked Immunoelectrotransfer Blot Techniques (EITB) for studying the specificities of antigens and antibodies separated by gel electrophoresis. Meth. Enzym. 92: 377-391, 1983.
  2. Sarngadharan MG, Popovic M, Bruch L, Schupbach J, Gallo RC. Antibodies reactive with Human T-Lymphotropic Retroviruses (HTLV-III) in the serum of patients with AIDS. Science. 224: 506-508, 1984.
  3. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 224: 497-500, 1984.
  4. Centers for Disease Control. Update on Acquired Immune Deficiency Syndrome (AIDS) - United States Mobidity and Mortality Weekly Report. 31:507-508, 1982.
  5. Steimer KS, Higgins KW, Powers MA, et al. Recombinant polypeptide from the endonuclease region of the Acquired Immune Deficiency Syndrome retrovirus polymerase (pol) gene detects serum antibodies in most infected individuals. J. Virol. 58:9-16, 1986.
  6. Veronese F, DeVico A, Copeland T, DeVico A, et al. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HIV/LAV. Science. 231: 1289-1291, 1986.
  7. Veronese F, Copeland T, Oroszland S, Gallo RC, Sarngadharan MG. Characterization of gp41 as the transmembrane protein coded by the HIV/LAV envelope gene. Science. 1402-1405, 1985.
  8. Sarngadharan MG, Veronese F, Lee S, Gallo RC. Immunological properties of HTLV-III antigens recognized by sera of patients with AIDS and AIDS-related complex and of asymptomatic carriers of HTLV-III infection. Cancer Res. 45: 4574s-4577s, 1985.
  9. Groopman JE, Chen FW, Hope JA, et al. Serological characterizatio of HIV infection in AIDS and related disorders. J. Inf. Dis. 153: 736-742, 1986.
  10. Pinter A, Honnen WJ, Tilley SA, et al. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type1. J. Virol. 63: 2674-9, 1989.
  11. Centers for Disease Control. Interpretation and use of the Western Blot Assay for Serodiagnosis of Human Immunodeficiency Virus Type I Infections. MMWR 38 (No. S-7):1-7, 1989.
  12. Hausler WJ. Report of the Third Consensus Conference on HIV Testing Sponsored by the Association of State and Territorial Public Health Laboratory Directors. Infect. Control Hosp Epidemiol. 9:345-349, 1988.
  13. Benenson S, Peddecord KM, Hofherr LK, Ascher MS, Taylor RN, Hearn TL. Reporting the Results of Human Immunodeficiency Virus Testing. JAMA 262, No. 24: 3435-3438, 1990.
  14. O’Gorman MRG, Weber D, Landis SE, et al. Interpretive Criteria of the Western Blot Assay for Serodiagnosis of Human Immunodeficiency Virus Type I Infection. Arch Pathol Lab Med 115: 26-30, 1991.

    15. Not Cited in Package Insert Sheet
  15. M’Boup S, Kanki P, Mhalu FS. Laboratory diagnosis of HIV-1 and HIV-2 in Africa. AIDS 5 (suppl 1): S93-S101, 1991.

Hydatid

  1. Schantz PM, Kramer MHJ. Larval cestode infections: cysticercosis and echinococcosis. Current Opinion in Infectious Diseases. 8: 342-350, 1995.
  2. Moro PL, et al.. Distribution of Hydatidosis and Cysticercosis in different Peruvian populations as demonstrated by an enzyme-linked immunoelectrotransfer blot (EITB) Assay. Am. J. Trop. Med. Hyg. 51 (6): 851-855, 1994.
  3. Verastegui M, et al. Enzyme-linked immunoelectrotransfer blot test for diagnosis of human hydatid disease. J. Clin. Micro. 30(6): 1557-1561, 1994.
  4. Moro PL, et al.. Immunoblot (Western Blot) and double diffusion (DD5) tests for hydatid disease cross-react with sera from patients with cysticercosis. Trans. Royal Soc. Trop. Med. Hyg. 86:422-423, 1992.
  5. Maddison SE, et al. A specific diagnostic antigen of Echinococcus granulosus with an apparent molecular weight of 8 kDa. Am. J. Trop. Med. Hyg. 40(4): 377-383, 1989.

Lyme

  1. Steere AC. 1989.  Lyme Disease. N. Engl. J. Med. 321:586-96.
  2. Burgdorfer W, Barbour AG, Hayes SF, et al. 1982.  Lyme disease- a tick borne spirochetosis? Science. 216:1317-19.
  3. Grodzicki RL, Steere AC. Comparison of immunoblotting and indirect enzyme-linked immunosorbent assay using different antigen preparations for diagnosing early Lyme disease. J. Infect. Dis. 157:79-97, 1988.
  4. Steere AC, Malawista SE. 1979.  Cases of Lyme disease in the United States: locations correlated with distribution of Ixodes dammini. Ann. Intern. Med. 91:730-3.
  5. Levine JF, Wilson ML, Spielman A.  1985.   Mice as reservoirs of the Lyme disease spirochete. Am. J. Trop. Med. Hyg. 34:355-60.
  6. Burgdorfer W, Lane RS, Barbour AG, Gresbrink RA, Anderson JR. 1985.  The western black-legged tick, Ixodes pacificus: a vector of Borrelia burgdorferi. Am. J. Trop. Med. Hyg. 34:925-30.
  7. Barbour AG, Hayes SF. 1986.  Biology of Borrelia species. Microbiol. Rev. 50(4):381-400.
  8. Dattwyler RJ. 1990.  Lyme borreliosis: an overview of clinical manifestations. Lab. Med. 21:290-292.
  9. Dattwyler, RJ. 1989.  Immunodiagnosis of Lyme borreliosis. Rheum. Dis. Clin. N. Am. 15:727-34.
  10. Szczepanski A, Benach J. 1991.  Lyme borreliosis: host responses to Borrelia burgdorferi. Microbiol. Rev. 55: 21-34.
  11. Craft JE, Grodzicki RL, Steere AC.  1984.   Antibody response in Lyme disease; evaluation of diagnostic tests. J. Inf. Dis. 149: 789-95.
  12. Craft JE, Fischer DK, Shimamoto GT, Steere AC. 1986.  Antigens of Borrelia burgdorferi recognized during Lyme disease.  Apearance of a new immunoglobulin M response and expansion of the immunoglobulin G late in the illness. J. Clin. Invest. 72: 504-515.
  13. CDC (1995)  Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease.  Mort. Morbid. Weekly Rep.  44:  590-1.
  14. Liang, F.T., Alvarez, A., Gu, Y., Nowling, J.M., Ramamoorthy, R., Philipp, M.T. 1999.  An Immunodominant conserved region within the variable domain of VlsE, the variable surface antigen of Borrelia burgdorferi.  J. Immunol. 163: 5566-5573.
  15. Liang, F.T., Steere, A.C., Marques, A.R., Johnson, B.J.B., Miller, J.N., Philipp, M.T. 1999.  Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi VlsE.  J. Clin. Microbiol.  37(12): 3990-3996.
  16. Liang, F.T. and Philipp, M.T. 1999.  Analysis of antibody response to invariable regions of VlsE, the variable surface antigen of Borrelia burgdorferi.  Infection and Immunity 67(12): 6702-6706.
  17. Liang, F.T., Aberer, E., Cinco, M., Gern, L., Hu, C.M., Lobet, Y.N., Ruscio, M., Voet, P.E., Jr., Weynants, V.E., Philipp, M.T. 2000.  Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of Borrelia burgdorferi SI.  J. Infectious Diseases 182: 1455-1462.
  18. Philipp, M.T., Bowers, L.C., Fawcett, P.T., Jacobs, M.B., Liang, F.T., Marques, A.R., Mitchell, P.D., Purcell, J.E., Ratterree, M.S., Straubinger, R.K. 2001.  Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental animals and in humans. J. Infect. Dis. 184: 870-878.

Not Cited in Package Insert
  1. Dorward DW, et al. Invasion and cytopathic killing of human lymphocytes by spirochetes causing Lyme Disease. Clin. Infect. Dis. 25 (Suppl 1): S2-8, 1997.
  2. Barthold SW, et al. Protective and arthritis resolving activity in sera of mice infected with Borrelia burgdorferi. Clin. Infect. Dis. 25 (Suppl 1): S9-17, 1997.
  3. Weis JJ, et al. Pathological manifestations in murine Lyme Disease: Association with tissue invasion and spirochete persistence. Clin. Infect. Dis. 25 (Suppl 1): S18-24, 1997.
  4. Pavia CS, Wormser GP, Norman GL. Activity of sera from patients with Lyme Disease against Borrelia burgdorferi. Clin. Infect. Dis. 25 (Suppl 1): S25-30, 1997.
  5. Tilton RC, Sand MN, Manak M. The western immunoblot for Lyme Disease: Determination of sensitivity, specificity, and interpretive criteria with use of commercially available performance panels. Clin. Infect. Dis. 25 (Suppl 1): S31-4, 1997.
  6. Persing DH. The cold zone: A curious convergence of tick transmitted diseases. Clin. Infect. Dis. 25 (Suppl 1): S35-42, 1997.
  7. Dumler JS. Is Human Granulocytic Ehrlichiosis a new Lyme Disease? Review and comparison of clinical, laboratory, epidemiological, and some biological features. Clin. Infect. Dis. 25 (Suppl 1): S43-7, 1997.
  8. Filking E, et al. Serologic diagnosis of Lyme Disease using recombinant outer surface proteins A and B and flagellin. J. Infect. Dis. 165: 1127-32, 1992.
  9. Schmitz JL, Powell CS, Folds JD. Comparison of seven commercial kits for detection of antibodies to Borrelia burgdorferi. Eur. J. Clin. Microbiol. Infect. Dis. June: 419-424, 1993.
  10. Huycke M, et al. Prevalence of antibody to Borrelia burgdorferi by indirect fluorescent antibody assay, ELISA, and western immunoblot in healthy adults in Wisconsin and Arizona. J. Infect. Dis. 165: 1133-7, 1992.
pix.GIF (45 bytes)

pix.GIF (45 bytes)

Immunetics, Inc.
27 Drydock Ave, 6th Floor, Boston MA 02210 USA
Tel: 617.896.9100    Toll-Free: 800.227.4765
Fax: 617.896.9110    email: info@immunetics.com